PMID- 38336982
OWN - NLM
STAT- Publisher
LR  - 20240209
IS  - 1699-3055 (Electronic)
IS  - 1699-048X (Linking)
DP  - 2024 Feb 9
TI  - Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert 
      opinion on adverse event management.
LID - 10.1007/s12094-024-03383-x [doi]
AB  - Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate that targets human 
      epidermal growth factor receptor 2 (HER2) and has shown promising results in the 
      treatment of advanced/metastatic breast cancer. The objective of this report is 
      to provide guidance on the prophylaxis, monitoring, and management of adverse 
      events (AEs) in patients with breast cancer treated with T-DXd, and to emphasize 
      that proper management of AEs is needed to optimize the effectiveness of T-DXd 
      treatment and reduce the number of discontinuations. The article covers various 
      aspects of T-DXd treatment, including its clinical efficacy, safety profile, and 
      dosing considerations, and provides practical recommendations for managing AEs, 
      such as nausea/vomiting, interstitial lung disease, and hematologic toxicity. 
      Although there are still many knowledge gaps about the cause and incidence of AEs 
      in real-world patients, this document may serve as a valuable resource for 
      clinicians who are involved in the care of breast cancer patients receiving T-DXd 
      treatment.
CI  - (c) 2024. The Author(s).
FAU - Ciruelos, Eva
AU  - Ciruelos E
AD  - Medical Oncology Unit, Hospital 12 de Octubre, Madrid, Spain.
FAU - Garcia-Saenz, Jose Angel
AU  - Garcia-Saenz JA
AD  - Medical Oncology Unit, Hospital Clinico San Carlos, Madrid, Spain.
FAU - Gavila, Joaquin
AU  - Gavila J
AD  - Medical Oncology Unit, Fundacion Instituto Valenciano de Oncologia, Valencia, 
      Spain.
FAU - Martin, Miguel
AU  - Martin M
AD  - Medical Oncology Unit, Hospital Gregorio Maranon, Madrid, Spain.
FAU - Rodriguez, Cesar A
AU  - Rodriguez CA
AD  - Medical Oncology Unit, Hospital Universitario de Salamanca-IBSAL, Salamanca, 
      Spain.
FAU - Rodriguez-Lescure, Alvaro
AU  - Rodriguez-Lescure A
AUID- ORCID: 0000-0002-6823-5290
AD  - Medical Oncology Unit, Hospital General Universitario de Elche, Alicante, Spain. 
      alescure@geicam.org.
LA  - eng
GR  - Funding of the writing of the manuscript/Daiichi Sankyo and AstraZeneca/
PT  - Journal Article
PT  - Review
DEP - 20240209
PL  - Italy
TA  - Clin Transl Oncol
JT  - Clinical & translational oncology : official publication of the Federation of 
      Spanish Oncology Societies and of the National Cancer Institute of Mexico
JID - 101247119
SB  - IM
OTO - NOTNLM
OT  - Adverse event management
OT  - Breast cancer
OT  - HER2
OT  - Trastuzumab deruxtecan
EDAT- 2024/02/10 10:51
MHDA- 2024/02/10 10:51
CRDT- 2024/02/09 23:57
PHST- 2023/10/09 00:00 [received]
PHST- 2024/01/04 00:00 [accepted]
PHST- 2024/02/10 10:51 [medline]
PHST- 2024/02/10 10:51 [pubmed]
PHST- 2024/02/09 23:57 [entrez]
AID - 10.1007/s12094-024-03383-x [pii]
AID - 10.1007/s12094-024-03383-x [doi]
PST - aheadofprint
SO  - Clin Transl Oncol. 2024 Feb 9. doi: 10.1007/s12094-024-03383-x.